Data availability The RNA sequencing datasets (GSE117930) and the single cell RNA sequencing datasets (GSE131508) are deposited in the Gene Expression Omnibus (GEO, NCBI) repository. The proteomic datasets are deposited in PRoteomics IDEntifications (PRIDE) repository (PXD010597). Author Contribution L.O. designed and performed most of the experiments, analysed and interpreted the data and contributed to the manuscript preparation. E.N. assisted with data collection, performed all the 3D-scaffold co-culture experiments, the in vivo Wisp1 experiments, the scRNA sequencing, interpreted and analysed the data and contributed to the manuscript preparation. I.K. performed the qPCR analysis, some of the tissue IF staining and analysed the data. A.M. and J.H.L. performed some of the tissue IF staining, all the lung organoid experiments, interpreted and analysed the data. V.B. performed some of the tissue IF staining. P.C. and S. H. performed bioinformatics analysis. I.H., J.K. and A.O. performed the proteomic and analysed the data. E.G.G. helped with the collection of Ly6G + cells for proteomics. G.M. performed the 3D-scaffold co-culture to analyse CD104 + cells. A.W. and L.C. performed the electron microscopy experiments. E.H. and V.S. provided human samples. L.O., E.N., I.K., V.B. and J.H.L., critically reviewed the manuscript. J.H.L., supervised the lung organoid experiments. I.M. designed and supervised the study, interpreted the data and wrote the manuscript.

Highlights Tocilizumab (TCZ) is currently being tested in COVID‐19‐induced cytokine storm. COVID-19 patients responding to TCZ have higher post-treatment levels of circulating miR-146a. Low levels of miR-146a are associated with death in COVID-19 patients not responding to TCZ. MicroRNAs can represent biomarkers of response to anti-inflammatory interventions in COVID-19.

Diabetic status is characterized by chronic low-grade inflammation and an increased burden of senescent cells. Recently, the senescence-associated secretory phenotype (SASP) has been suggested as a possible source of inflammatory factors in obesity-induced type 2 diabetes. However, while senescence is a known consequence of hyperglycaemia, evidences of SASP as a result of the glycaemic insult are missing. In addition, few data are available regarding which cell types are the main SASP-spreading cells in vivo.Adopting a four-pronged approach we demonstrated that: i) an archetypal SASP response that was at least partly attributable to endothelial cells and macrophages is induced in mouse kidney after in vivo exposure to sustained hyperglycaemia; ii) reproducing a similar condition in vitro in endothelial cells and macrophages, hyperglycaemic stimulus largely phenocopies the SASP acquired during replicative senescence; iii) in endothelial cells, hyperglycaemia-induced senescence and SASP could be prevented by SOD-1 overexpression; and iiii) ex vivo circulating angiogenic cells derived from peripheral blood mononuclear cells from diabetic patients displayed features consistent with the SASP.Overall, the present findings document a direct link between hyperglycaemia and the SASP in endothelial cells and macrophages, making the SASP a highly likely contributor to the fuelling of low-grade inflammation in diabetes.

No abstract

Metabolic syndrome is a cluster of risk factors that lead to cardiovascular morbidity and mortality. Recent studies linked metabolic syndrome and several types of cancer. Although metabolic syndrome may not necessarily cause cancer, it is linked to poorer cancer outcomes including increased risk of recurrence and overall mortality. This review tends to discuss the major biological and physiological alterations involved in the increase of incidence and mortality of cancer patients affected by metabolic syndrome. We focus on metabolic syndrome-associated visceral adiposity, hyperinsulinemia, hyperglycemia, insulin-like growth factor (IGF-I) pathway as well as estrogen signaling and inflammation. Several of these factors are also involved in carcinogenesis and cancer progression. A better understanding of the link between metabolic syndrome and cancer may provide new insight about oncogenesis. Moreover, prevention of metabolic syndrome – related alterations may be an important aspect in the management of cancer patients during simultaneous palliative care.